Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 68.7%

Neg 68.7% Neu 0% Pos 0%

Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.